London-based pharmaceutical company GlaxoSmithKline has agreed to pay $90 million to 38 states to settle allegations it unlawfully promoted its diabetes treatment Avandia (rosiglitazone), several state attorneys general said Nov. 15.
In addition, under the settlement, GSK also will be required to change the way it promotes its diabetes drugs, including Avandia.
Among the states’ allegations are that GSK failed to report certain safety data related to Avandia, and violated consumer protection laws by misrepresenting the risk of heart attack associated with Avandia; the safety of using Avandia alone; and the safety of using Avandia in conjunction with other diabetes ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.